Evotec and Bristol Myers win FDA clearance for second drug candidate
The cereblon E3 ligase modulator is scheduled to enter Phase 1 trials in 2027 under an oncology-focused molecular glue pact first signed in 2018.

Evotec SE and Bristol Myers Squibb received clearance on Nov. 19 from the U.S. Food and Drug Administration for a second investigational drug candidate developed under their protein degradation alliance.
The cereblon E3 ligase modulator, known as a CELMoD, advances an eight-year-old discovery collaboration designed to target undruggable disease proteins, with clinical trials slated for 2027 following a first oncology candidate in March 2026.
"The progression of a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform," said Dr. Joanna Holbrook, chief scientific officer of Evotec, in a press release on Nov. 19. "We are systematically translating complex biology into development candidates. This achievement reinforces the value of our longstanding collaboration with Bristol Myers Squibb and further strengthens our confidence in the platform's potential to generate a growing pipeline of investigational drug candidates aimed at addressing substantial unmet medical needs."
Conventional small molecules rely on direct binding to disrupt receptor function, leaving roughly 90% of target proteins unreachable, according to Evotec. In contrast, molecular glues induce proximity between an E3 ubiquitin ligase and disease-relevant proteins to trigger their degradation, expanding potential interventions in oncology and other therapeutic fields.
The companies established their molecular glue partnership in 2018, when Evotec teamed with Celgene before its acquisition by Bristol Myers Squibb. The pact was broadened in 2022, pairing Evotec's PanOmics screening pipelines and PanHunter computational platform with Bristol Myers Squibb's specialized CELMoD library.
The initial molecule from the collaboration entered Phase 1 clinical development in March 2026 for patients with advanced clear cell renal cell carcinoma. The latest regulatory clearance follows an R&D leadership overhaul at Bristol Myers Squibb intended to bolster late-stage development in response to looming patent expirations, as Atlas360 reported in November.
Bristol Myers Squibb and Evotec plan to advance the newly cleared candidate into Phase 1 clinical trials in 2027.
Source: Press release, Evotec SE, Nov. 19, 2026.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- GSK wins FDA approval for Nelkarmi after 49% response rate
- Europe faces 35,000 drug-resistance deaths a year
- U.S. women report frequent fatigue at 20% rate
- CDC to aid Pennsylvania measles response after 1,222 cases
Latest news
- Social Security raises 2027 benefits 3.6%
- Hull City 2–0 Brighton: When Resilience Beat Reputation
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence

